Cardium Therapeutics, Inc. is an asset-based, health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and its recently-acquired To Go Brands nutraceutical supplement business.
The company's lead commercial product Excellagen® topical gel for wound care management received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium has initiated its ASPIRE Phase 3 / registration study in Russia.
To Go Brands® healthy nutraceutical supplement business has over 25 products being developed and sold by food, drug and mass channel retailers.
Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value.
Excellagen - New Wound Care Pathway for Diabetic Foot Ulcers
Cardium's new Excellagen highly-refined fibrillar flowable bovine collagen topical gel (2.6%) is a professional-use wound care product for the treatment of diabetic foot ulcers, pressure ulcers and other dermal wounds.
Christopher J. Reinhard, Chairman of the Board, CEO, President and Treasurer
Mr. Reinhard is a co-founder of Cardium and has served as a director and the Chief Executive Officer, President and Treasurer of Cardium since its inception in December 2003. Mr. Reinhard has also served as a director and the Chief Executive Officer and President of Tissue Repair Company, a wholly-owned subsidiary of Cardium since August 2006. He served as a director and the Chief Executive Officer and Treasurer of Cardium’s InnerCool Therapies subsidiary from its acquisition in March 2006 until its sale to Royal Philips Electronics in July 2009. For almost 15 years, Mr. Reinhard has focused on the commercial development of cardiovascular growth factor therapeutics. Before founding Cardium, he was a co-founder of Collateral Therapeutics, Inc., and served as a director (from 1995) and President (from 1999) of Collateral until its 2002 acquisition by the Schering Group, Germany (now part of Bayer HealthCare). He continued as Chief Executive of Collateral through December 2004. Mr. Reinhard played a major role in effecting Collateral’s initial public offering led by Bear Stearns & Co. in 1998, and the sale of Collateral to Schering. Mr. Reinhard also served as Executive Chairman of Artes Medical from 2004 to 2008. Previously, Mr. Reinhard was Vice President and Managing Director of the Henley Group, a publicly-traded diversified industrial and manufacturing group, and Vice President of various public and private companies created by the Henley Group through spin-out transactions, including Fisher Scientific Group, a leading international distributor of laboratory equipment and test apparatus for the scientific community, Instrumentation Laboratory and IMED Corporation, a medical device company. Mr. Reinhard received a B.S. in Finance and an M.B.A. from Babson College.
Tyler M. Dylan-Hyde, Ph.D., J.D., Director, CBO, Gen Counsel, Exec VP & Secretary
Dr. Dylan-Hyde is a co-founder of Cardium and has served as a director and as the company’s General Counsel, Executive Vice President and Secretary since its inception in December 2003, and as its Chief Business Officer since May 2005. Since August 2006, Dr. Dylan-Hyde has also served as a director and Chief Business Officer, General Counsel, Executive Vice President and Secretary of Tissue Repair Company, a wholly-owned subsidiary of Cardium. He served as a director and Chief Business Officer of Cardium’s InnerCool Therapies subsidiary from its acquisition in March 2006 until its sale to Royal Philips Electronics in July 2009. Dr. Dylan-Hyde has focused on the development of biologics and devices for cardiovascular and ischemic diseases for more than a decade. He served as General Counsel and Vice President of Collateral Therapeutics, Inc. until its 2002 acquisition by the Schering Group, Germany (now part of Bayer HealthCare). Dr. Dylan-Hyde played a major role in developing Collateral’s intellectual property portfolio, in furthering its business development efforts and in advancing the company toward and through its acquisition by Schering, and continued as an executive officer and later consultant until 2005. Dr. Dylan-Hyde has advised both privately-held and publicly-traded companies that are developing, partnering or commercializing technology-based products. Before joining Collateral, Dr. Dylan-Hyde was a partner of the law firm of Morrison & Foerster LLP. In his law firm practice, he focused on the development, acquisition and enforcement of intellectual property rights, as well as related business and transactional issues. He also has worked with both researchers and business management in the biotech and pharmaceutical industries. Dr. Dylan-Hyde received a B.Sc. in Molecular Biology from McGill University, Montreal, Canada, a Ph.D. in Biology from the University of California, San Diego, where he performed research at the Center for Molecular Genetics, and a J.D. from the University of California, Berkeley.
Dennis M. Mulroy, CPA, Chief Financial Officer
Mr. Mulroy has been the Chief Financial Officer of Cardium since November 2005. He has also served as a director, Chief Financial Officer and Treasurer of Tissue Repair Company, a wholly-owned subsidiary of Cardium since August 2006. He served as a director and the Chief Financial Officer and Treasurer of Cardium’s InnerCool Therapies subsidiary from its acquisition in March 2006 until its sale to Royal Philips Electronics in July 2009. Mr. Mulroy was Chief Financial Officer of Molecular Imaging Corporation, a publicly-traded diagnostic services company (January 2004 – November 2005), SeraCare Life Sciences, Inc., a publicly-traded company (November 2001 – June 2003), and Bioceutix Inc. (January 2001 – November 2001). Mr. Mulroy was also employed with Ernst & Young in San Diego, California and is a Certified Public Accountant in the State of California. He received his degree in Business Administration from the University of San Diego.
Gabor M. Rubyani, M.D., Ph. D., Chief Scientific Officer
Dr. Rubanyi has been the Chief Scientific Officer of Cardium since June 2006. From November 2005 until March 2006, he provided consulting services to Cardium. In March 2006, Dr. Rubanyi became an employee and a Scientific Advisor of Cardium. Before joining Cardium in March 2006, Dr. Rubanyi was Vice President of Gene Therapy at Berlex Biosciences (a subsidiary of Berlex Laboratories, the U.S. pharmaceutical affiliate of the Schering AG Group, Germany), and Adjunct Professor at the University of California, Davis. He initiated and played a leading role in the Angiogenic Gene Therapy for Coronary Artery Disease project at Schering/Berlex. Formerly, Dr. Rubanyi was Director of Vascular and Endothelial Research at Berlex (1992-1999), Director of the Institute of Pharmacology at Schering AG, Research Center, Berlin, Germany (1990-1992), Director of Pharmacology at Berlex Laboratories (1987-1990), and Associate Professor at the Mayo Clinic Medical School (1983-1987). Since 2006, Dr. Rubanyi has served as a director of Hybrid Systems, Ltd., a private, United Kingdom biotech company. Dr. Rubanyi is the author or co-author of 22 books and over 325 research articles, serves as an editorial board member to several biomedical journals and is the founder of the biomedical journal Endothelium. He also is a member of numerous American and international scientific societies. His pioneering work on the nature and characterization of endothelium-derived relaxing factors (nitric oxide) and contracting factors (endothelin) contributed substantially to the Company's present knowledge about endothelial control of vascular function in health and disease, including angiogenesis.
Robert L. Engler, M.D., Chief Medical Advisor
Dr. Engler was co-founder of Collateral Therapeutics and served as a Director from 1995 to 2000 and as Vice President -- Medical Director from 1995 through 1998. Currently, Dr. Engler is Professor of Medicine Emeritus at the University of California, San Diego (UCSD). He was Professor of Medicine at UCSD, Associate Chief of Staff for Research and Development at the Veterans' Affairs Medical Center, and a faculty member of the Institute for Biomedical Engineering at UCSD. He served as director of Coronary Care at the VA Hospital and was a clinical cardiologist until 2001 when he retired from UCSD and the VA Hospital to continue his work in the development of innovative agents for cardiovascular therapy. From 1985 to 1997, Dr. Engler was a Scientific Advisor to Gensia. Dr. Engler is a director of Halozyme Therapeutics, a publicly-traded biotechnology company. He received a B.A. in Physics from the University of North Carolina and his medical degree from Georgetown University.